Clinical, biochemical and radiological retrospective analysis in patients with adrenal incidentaloma

Yıl 2022, Cilt: 15 Sayı: 2, 382 - 392, 31.08.2022

Zeynep Ebru Eser , Ramazan Gen , Kadir Eser , Kerem Sezer , Esen Akbay

https://doi.org/10.26559/mersinsbd.1109724

Öz

Introduction: The aim of this study was to evaluate the epidemiological, demographic, clinical features, treatment approaches and survival of patients followed up for adrenal incidentaloma. Methods: The data of 46 patients who underwent treatment and follow-up for adrenal incidentaloma in Mersin University Health Research and Practice Hospital, Endocrinology Department between 2010 and 2014 were retrospectively analyzed. Results: The study group consisted of 13 male and 33 female patients. The mean age was 54.09 ± 10.7 years. The most common reason for admission was abdominal pain in 34.78% of patients, the most commonly diagnosed radiological method was 60.87% dynamic surrenal CT, and the most common localization was right surrenal gland. The mean diameter of the mass was 26.8±16.5 mm. The prevalence of hypertension was 50%, obesity was 47.8%, type 2 diabetes was 21.7%, osteoporosis was 42.8% and metabolic syndrome was 41.3%. According to the results of hormonal evaluation, 82.61% of the patients had dysfunctional adrenal adenoma (FAA), 15.21% of them had subclinical Cushing syndrome (SCS) and 2.1% of them had aldesteronoma. Myelolipoma, benign pheochromocytoma and adrenocortical adenoma were diagnosed in 8 patients who underwent adrenalectomy. One patient died due to liver failure. No hormonal activation and lesion size growth was detected in the follow-up of the patients. Conclusion: Because of the different pathological and radiological features of AI, it is important to evaluate demographic, etiological, clinical, laboratory and radiological data as a whole in treatment and follow-up.

Anahtar Kelimeler

Adrenal incidentaloma , subclinical Cushing syndrome , dysfunctional adrenal adenoma , diagnosis , treatment

Proje Numarası

yok

Adrenal insidentaloma’lı hastalarda klinik, biyokimyasal ve radyolojik retrospektif analiz

Öz

Giriş: Bu çalışmada, adrenal insidentaloma nedeniyle takip edilen hastaların epidemiyolojik, demografik, klinik özellikleri, tedavi yaklaşımları ve yaşam sürelerinin değerlendirilmesi amaçlanmıştır. Yöntem: 2010–2014 yılları arasında Mersin Üniversitesi Araştırma ve Uygulama Hastanesi Endokrinoloji Bölümünde adrenal insidentaloma nedeniyle tedavi ve takipleri yapılan 46 hastanın verileri retrospektif olarak incelendi. Bulgular: Çalışmaya alınan olguların 13’ü erkek, 33’ü kadın ve yaş ortalaması 54.09±10.7 idi. En sık başvuru nedeni %34.78 hastada karın ağrısı, en sık tanı konulan radyolojik yöntem % 60.87 dinamik sürrenal BT, en sık yerleşim yeri sol surrenal bezdi. Kitle çapı ortalama 26.8±16.5 mm arasında idi. Hipertansiyon sıklığı %50, obezite sıklığı %47.8, tip 2 diyabet sıklığı %21.7, osteoporoz sıklığı ise %42.8 ve metabolik sendrom sıklığı %41.3 olarak saptandı. Hormonal değerlendirme sonuçlarına göre %82.61’inde fonksiyonsuz adrenal adenom (FAA), %15.21’inde subklinik Cushing sendromu (SCS), %2.1’inde aldesteronoma görüldü. Adrenalektomiye giden 8 olguda myelolipom, feokromasitoma ve adrenokortikal adenom tanısı konuldu. Bir hasta karaciğer yetmezliğinden exitus oldu. Hastaların takiplerinde hormonal aktivasyon ve lezyon boyutunda büyüme saptanmadı. Sonuç: AI’ların çok farklı patolojik ve radyolojik görünümler ile karşımıza çıkmasından dolayı demografik, etiyolojik, klinik, laboratuar ve radyolojik verilerin bir bütün olarak değerlendirilmesi tedavi ve takibinde önemlidir.

Anahtar Kelimeler

Adrenal insidentaloma , subklinik cushing sendromu , fonksiyonsuz adrenal adenom , teşhis , tedavi

Destekleyen Kurum

yok

Proje Numarası

yok

Teşekkür

yok

Kaynakça

• Hsieh LB, Mackinney E, Wang TS.When to Intervene for Subclinical Cushing's Syndrome. Surg Clin North Am. 2019 Aug;99(4):747-758. doi: 10.1016/j.suc.2019.04.011. Epub 2019 May 27. Review.
• Jason DS, Oltmann SC. Evaluation of an Adrenal Incidentaloma. Surg Clin North Am. 2019 Aug;99(4):721-729. doi: 10.1016/j.suc.2019.04.009. Epub 2019 May 9. Review.
• Cyranska-Chyrek E, Szczepanek-Parulska E, Olejarz M, Ruchala M.Malignancy Risk and Hormonal Activity of Adrenal Incidentalomas in a Large Cohort of Patients from a Single Tertiary Reference Center. Int J Environ Res Public Health. 2019 May 27;16(10). pii: E1872. doi: 10.3390/ijerph16101872.
• Taya M, Paroder V, Bellin E, Haramati LB. The relationship between adrenal incidentalomas and mortality risk. Eur Radiol. 2019 Apr 16. doi: 10.1007/s00330-019-06202-y. [Epub ahead of print].
• Maher DI, Williams E, Grodski S, Serpell JW, Lee JC. Adrenal incidentalomafollow-up is influenced by patient, radiologic, and medical provider factors: A review of 804 cases. Surgery. 2018 Dec;164(6):1360-1365. doi: 10.1016/j.surg.2018.07.011. Epub 2018 Aug 28.
• Celejewski K, Pogorzelski R, Toutounchi S, et al. Adrenal Incidentaloma- Diagnostic and Treating Problem - Own Experience. Open Med (Wars). 2018 Aug 15;13:281-284. doi: 10.1515/med-2018-0043. ECollection 2018.
• Morelli V, Palmieri S.Adrenal incidentaloma: differential diagnosis and management strategies. Minerva Endocrinol. 2019 Mar;44(1):4-18. doi: 10.23736/S0391-1977.18.02868-7. Epub 2018 May 28. Review.
• Kerkhofs TM, Roumen RM, Demeyere TB, van der Linden AN, Haak HR. Adrenal tumors with unexpected outcome: a review of the literature. Int J Endocrinol.2015;2015:710514. doi: 10.1155/2015/710514. Epub 2015 Mar 25.)
• Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev, 1995; 16: 460-84.
• Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637–44.
• Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumours: endocrine and scintigraphic correlates. J Clin Endocrinol Metab. 1998, 83; 55-62.
• Chidiac RM, Aron DC. Incidentalomas. A disease of modern technology. Endocrinol Metab Clin North Am, 1997; 26: 233-253.
• Reincke M, Nieke J, Krestin GP, et al. Preclinical Cushing’s syndrome in adrenal incidentaloma: comparison with adrenal Cushing’s syndrome. J Clin Endocrinol Metab. 1992; 75: 826-832.
• Morioko M, Fujii T, Matsuki T, et al. Preclinical Cushing’s syndrome: report of seven cases and review of the literature. Int J Urology, 2000; 7: 126-132.
• Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab, 2000; 85: 1440-1448.
• Libe R, Dall’Asta C, Barbetta L, et al. Long term follow up study of patients with adrenal incidentalomas. Eur J Endocrinol, 2002; 147: 489-494.
• Kasperlik-Zeluska, AA, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf), 1997; 46-1: 29-37.
• Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am, 2000; 29-1: 43-56
• Tsagarakis S, Roboti C, Kokkoris P, et al. Elevated postdexamethasone suppression cortisol concentrations corralate with hormonal alterations of the hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol(Oxf), 1998; 49: 165-171
• Bardet S, Rochmer V, Murat A, et al. 131I-6-iodomethylnorcholesterol scintigraphy: an assessment of oits role in the investigation of adrenocortical incidentalomas. Clin Endocrinol, 1996; 44: 587-596.
• Ambrosi B, Passini E, et al. The clinical evaluation of silent adrenal masses. J Endocrinol Invest, 1997; 20: 90-107
• Comlekci A, Yener S, Ertilav S, et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 2010;37:40–6.
• Angeli A, Terzolo M. Adrenal incidentaloma- a modern disease with old Complications (editorial comment). J Clin Endocrinol Metab, 2002; 87: 4869- 4871.
• Angeli A, Osella G, Ali A, Terzolo M. Adrenal insidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res, 1997; 47: 279-283.
• Yener S, Ertilav S, Secil M, at al. Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas. Med Princ Pract. 2012;21(5):429-34.
• Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593-5602.
• Chiodini I, Torlantano M, Carnevale V, et al. Bone loss rate in adrenal incidentalomas: a longitudinal study. J Clin Endocrinol Metab, 2001; 86: 5337- 5341
• Chiodini I, Tauchmanova L, Torlantano M, et al. Bone involvement in eugonodal male patients with adrenal incidentaloma and subclinical hypercortisolism. J Clin Endocrinol Metab, 2002; 87: 5491-5494.
• Tauchmanova L, Rossi R, Nuzzo V, et al. Bone loss determined by quantitative ultrasonometry coorelates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol, 2001; 145: 241-247